Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients

Table 2 Clinicopathologic characteristics of colorectal cancer patients with loss of CDX2 expression n (%)

Parameters	CDX2-retained671 (94.1)	Loss of CDX2 expression42 (5.9)	P value
Age (median)	60.9 ± 11.5	62.2 ± 12.1	0.5031
Sex			0.070
Male	414 (61.7)	20 (47.6)
Female	257 (38.1)	22 (52.4)
Location			< 0.001
Proximal colon	166 (24.7)	25 (59.5)
Distal colon	276 (41.1)	10 (23.8)
Rectum	229 (34.1)	7 (16.7)
Gross type			0.009
Fungating	451 (67.2)	20 (47.6)
Ulcerative	220 (32.8)	22 (52.4)
T category			0.005
T1, 2	135 (20.1)	1 (2.4)
T3, 4	536 (79.9)	41 (97.6)
N category			< 0.001
N0	355 (52.9)	10 (23.8)
N1, 2	316 (47.1)	32 (76.2)
M category			0.039
M0	562 (83.8)	30 (71.4)
M1	109 (16.2)	12 (28.6)
Stage			< 0.001
I, II	331 (49.3)	9 (21.4)
III, IV	340 (50.7)	33 (78.6)
Adjuvant chemotherapy			0.854
Not treated	233 (34.7)	14 (33.3)
Treated	438 (65.3)	28 (66.7)

¹Student’s t test. HPF: High power field. Cut-off for loss of CDX2 expression: < 20% of tumor cells showing nuclear positivity.